Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease

Source : https://www.jacc.org/doi/abs/10.1016/j.jacc.2021.04.060

Circulating miRNAs miR-574-5p and miR-3135b are potential metabolic regulators for serum lipids and blood glucose in gestational diabetes mellitus

Source : https://doi.org/10.1080/09513590.2021.1908990

Abstract MicroRNAs (miRNAs) are potentially involved in the regulation of glucose and lipid metabolism. The aim of this study was to investigate potential miRNA regulators for serum lipids and blood...

Novel biomarker panel measuring endothelial injury identifies patients at risk of coronary artery syndrome and discordance with low-density lipoprotein cholesterol.

Source : https://europepmc.org/article/med/34138801

Background Individuals with no history of coronary artery disease can develop acute coronary syndrome (ACS), often in the absence of major risk factors including low-density lipoprotein cholesterol (LDL-C). We identified...

Is There Less Aggressive Lipid Management in PAD Patients? - American College of Cardiology

Source : https://www.acc.org/latest-in-cardiology/articles/2021/06/14/20/40/is-there-less-aggressive-lipid-management-in-pad-patients

For patients with peripheral artery disease (PAD), intensity of lipid-lowering therapy may be a "poor surrogate" for achieved LDL-cholesterol (LDL-C), as achieved LDL-C levels remain elevated for the majority of...

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Source : https://www.cureus.com/articles/61261-atrial-fibrillation-as-a-possible-adverse-reaction-to-evolocumab

Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease....